Xeris Pharmaceuticals (NASDAQ:XERS) reported positive topline results from its Phase 2 study of XP-3924, a pramlintide-insulin co-formulation, in adults with Type 1 diabetes (T1D).
The trial enrolled 18 adults with T1D who received either XP-3924 with 50% insulin reduction (which offsets the addition of pramlintide); regular insulin; or regular insulin with 50% insulin reduction plus pramlintide co-administered as separate injections.
Subjects’ blood glucose levels were monitored for six hours after drug dosing. Treatment with XP-3924 resulted in a 62% reduction of hyperglycemia after the glucose challenge, compared with regular insulin.
“Results from our proof-of-concept study demonstrate that XP-3924, our XeriSol pramlintide-insulin co-formulation, reduced postprandial glycemic excursions and has the potential to significantly improve the management of glycemic conditions of people with diabetes,” Paul Edick, Xeris’ chairman and CEO, said in a statement.
“Pramlintide has many patient benefits yet is underutilized because of its additional daily injection burden. We believe our XP-3924 co-formulation can reduce this burden and may improve long-term pramlintide treatment adherence and persistency,” he added.
